Clinical Trial Detail

NCT ID NCT03940703
Title A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed Mesenchymal-epithelial Transition Factor (MET) Amplified Non-small Cell Lung Cancer (NSCLC) (INSIGHT 2) (INSIGHT 2)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors EMD Serono Research & Development Institute, Inc.
Indications

lung non-small cell carcinoma

Therapies

Osimertinib + Tepotinib

Tepotinib

Age Groups: adult senior

No variant requirements are available.